Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0L1JE
|
|||
| Former ID |
DIB013060
|
|||
| Drug Name |
CJC-1131
|
|||
| Synonyms |
CJC-1131-albumin bioconjugate; DAC:GLP-1; Glucagon-like peptide 1, ConjuChem
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Type-1 diabetes [ICD-11: 5A10; ICD-9: 250] | Discontinued in Phase 2 | [1] | |
| Company |
ConjuChem Biotechnologies Inc
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C168H254N44O52
|
|||
| Canonical SMILES |
CCC(C)C(C(=O)NC(C)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCCN)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCNC(=O)COCCOCCNC(=O)CCN3C(=O)C=CC3=O)C(=O)N)NC(=O)C(CC4=CC=CC=C4)NC(=O)C(CCC(=O)O)NC(=O)C(CCCCN)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC5=CC=C(C=C5)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC6=CC=CC=C6)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CC7=CNC=N7)N
|
|||
| InChI |
1S/C168H254N44O52/c1-17-89(10)137(165(260)188-93(14)144(239)197-118(72-99-75-180-104-38-25-24-37-102(99)104)155(250)199-114(68-86(4)5)156(251)208-135(87(6)7)163(258)196-106(40-26-29-58-169)146(241)181-77-125(221)189-107(42-32-61-179-168(174)175)150(245)191-105(140(173)235)39-28-31-60-177-128(224)83-264-66-65-263-64-62-178-124(220)57-63-212-129(225)52-53-130(212)226)210-157(252)116(69-96-33-20-18-21-34-96)200-152(247)112(50-56-133(231)232)195-151(246)108(41-27-30-59-170)192-142(237)91(12)185-141(236)90(11)187-149(244)111(47-51-123(172)219)190-126(222)78-182-148(243)110(49-55-132(229)230)194-153(248)113(67-85(2)3)198-154(249)115(71-98-43-45-101(218)46-44-98)201-160(255)120(80-213)204-162(257)122(82-215)205-164(259)136(88(8)9)209-159(254)119(74-134(233)234)202-161(256)121(81-214)206-167(262)139(95(16)217)211-158(253)117(70-97-35-22-19-23-36-97)203-166(261)138(94(15)216)207-127(223)79-183-147(242)109(48-54-131(227)228)193-143(238)92(13)186-145(240)103(171)73-100-76-176-84-184-100/h18-25,33-38,43-46,52-53,75-76,84-95,103,105-122,135-139,180,213-218H,17,26-32,39-42,47-51,54-74,77-83,169-171H2,1-16H3,(H2,172,219)(H2,173,235)(H,176,184)(H,177,224)(H,178,220)(H,181,241)(H,182,243)(H,183,242)(H,185,236)(H,186,240)(H,187,244)(H,188,260)(H,189,221)(H,190,222)(H,191,245)(H,192,237)(H,193,238)(H,194,248)(H,195,246)(H,196,258)(H,197,239)(H,198,249)(H,199,250)(H,200,247)(H,201,255)(H,202,256)(H,203,261)(H,204,257)(H,205,259)(H,206,262)(H,207,223)(H,208,251)(H,209,254)(H,210,252)(H,211,253)(H,227,228)(H,229,230)(H,231,232)(H,233,234)(H4,174,175,179)/t89-,90-,91-,92+,93-,94+,95+,103-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,135-,136-,137-,138-,139-/m0/s1
|
|||
| InChIKey |
AIWAEWBZDJARBJ-PXUUZXDZSA-N
|
|||
| CAS Number |
CAS 532951-64-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Glucagon-like peptide 1 receptor (GLP1R) | Target Info | Modulator | [2] |
| KEGG Pathway | cAMP signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Insulin secretion | ||||
| Reactome | Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | |||
| G alpha (s) signalling events | ||||
| Glucagon-type ligand receptors | ||||
| WikiPathways | GPCRs, Class B Secretin-like | |||
| Integration of energy metabolism | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015896) | |||
| REF 2 | Pharmacokinetics and tolerability of a novel long-acting glucagon-like peptide-1 analog, CJC-1131, in healthy and diabetic subjects. Int J Clin Pharmacol Ther. 2008 Sep;46(9):443-52. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.